Over 70% of breast cancers show activation of the PI3K pathway through mechanisms such as HER2 amplification, deletion of the tumor suppressor PTEN, or oncogenic mutations in PIK3CA (Zhao and Vogt, 2008). The gene discussed is ERBB2; the disease is breast carcinoma.